Home > Healthcare > Pharmaceuticals > Finished Drug Form > Heparin Market

Heparin Market Trends

Report ID: GMI4837
Published Date: Feb 2022
Report Format: PDF

Download Free Sample

Heparin Market Trends

Recent advancements in hemodialysis have created lucrative opportunities for market progression. These advancements have increased the demand for high-flux dialyzers, which enhance clearance rates for toxins and fluid removal and require longer treatment times. To prevent clotting in the dialysis circuit during these prolonged treatments, heparin is commonly used as an anticoagulant. Researchers are actively exploring and developing heparin-sparing techniques in hemodialysis, which will positively impact industry expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

In 2022, the heparin industry size was valued at more than USD 4.8 billion in 2022 and will grow at over 2.5% CAGR from 2023 to 2032, attributed to the growing occurrence of chronic disorders globally.

The low molecular weight heparin industry was worth over USD 4.2 billion in 2022, owing to the rising prevalence of deep vein thrombosis.

Europe heparin market held more than 58.5% market share in 2022, on account of the surging prevalence of venous thromboembolism, ischemic heart disease, and other cardiovascular diseases that lead to blood clot formation in the region.

Major heparin industry players include Amphastar, Leo Pharma, Rovi, Sanofi, Changzhou Qianhong Biopharma, Pfizer, Shenzhen Hepalink, and Nanjing King-Friend Biochemical Pharmaceutical, among others.